Trial Details
RECRUITINGBasic Information
| Clinical ID | c231 |
|---|---|
| Identifier | NCT06925061 |
| Trial Title | Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn Disease (CD) |
| Interventions | DRUG: After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks |
Participant Information
| Sponsor | Madeleine Bezault |
|---|---|
| City | Clermont-Ferrand |
| Country/Region | France |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-03-31 |
|---|---|
| Primary Completion Date | 2026-09-13 |
| Completion Date | 2026-12-31 |